November 21, 2016 - By Winifred Garcia · 0 Comments
Evoke Pharma Inc (NASDAQ:EVOK) institutional sentiment decreased to 1.33 in Q2 2016. Its down -1.34, from 2.67 in 2016Q1. The ratio worsened, as 8 investment managers opened new or increased holdings, while 3 trimmed and sold holdings in Evoke Pharma Inc. The investment managers in our partner’s database now own: 1.01 million shares, up from 386,180 shares in 2016Q1. Also, the number of investment managers holding Evoke Pharma Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 2 Increased: 6 New Position: 2.
Evoke Pharma, Inc. is a specialty pharmaceutical company. The company has a market cap of $22.36 million. The Firm is focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. It currently has negative earnings. The Firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
It is down 65.50% since April 19, 2016 and is downtrending. It has underperformed by 69.36% the S&P500.
According to Zacks Investment Research, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.”
Opaleye Management Inc. holds 2.95% of its portfolio in Evoke Pharma Inc for 695,000 shares. Knoll Capital Management Lp owns 55,660 shares or 0.12% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 2,887 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 12,092 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 2 sales for $1.65 million net activity.
Ratings analysis reveals 50% of Evoke Pharma’s analysts are positive. Out of 6 Wall Street analysts rating Evoke Pharma, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $2 while the high is $27. The stock’s average target of $14 is 686.52% above today’s ($1.78) share price. EVOK was included in 9 notes of analysts from August 20, 2015. The firm has “Buy” rating by Rodman & Renshaw given on Friday, October 2. The firm has “Buy” rating given on Thursday, August 20 by Brean Capital. H.C. Wainwright initiated the shares of EVOK in a report on Thursday, October 1 with “Buy” rating. The stock of Evoke Pharma Inc (NASDAQ:EVOK) has “Hold” rating given on Tuesday, July 19 by Noble Financial. The firm earned “Buy” rating on Monday, March 14 by Ascendiant Capital. The stock of Evoke Pharma Inc (NASDAQ:EVOK) earned “Hold” rating by Brean Capital on Monday, July 18. Northland Capital initiated the shares of EVOK in a report on Wednesday, March 16 with “Outperform” rating. On Monday, July 18 the stock rating was downgraded by Rodman & Renshaw to “Neutral”.
Evoke Pharma, Inc., incorporated on January 29, 2007, is a specialty pharmaceutical company. The Firm is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration.
More notable recent Evoke Pharma Inc (NASDAQ:EVOK) news were published by: Marketwatch.com which released: “Evoke Pharma stock drops 76% after drug’s late-stage topline results miss …” on July 18, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on November 03, 2013, Seekingalpha.com published: “Evoke Pharma: Hop On And Ride The Elevator Higher” on July 31, 2016. More interesting news about Evoke Pharma Inc (NASDAQ:EVOK) were released by: 247Wallst.com and their article: “Is the FDA Changing Its Tune on Evoke Pharma?” published on September 07, 2016 as well as Globenewswire.com‘s news article titled: “Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for …” with publication date: July 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia